Treating High-Risk Patients with Non-Statin Therapy for LDL-C Lowering: Optimizing Clinical Outcomes

Non-statin therapies such as ezetimibe and PCSK9 inhibitors have demonstrated benefits in lowering LDL-C and reducing the risk of major adverse cardiovascular events in high risk patients.

Lipid Management, Pharmacology, Risk Assessment and Management
Member Cost: $0Non-member Cost: $0
Credits: 1.0 CE contact hours, 0.8 CE pharmacology hours

Course Overview

 

Learn how non-statin therapies such as ezetimibe and PCSK9 inhibitors have demonstrated benefits in lowering LDL-C and reducing the risk of major adverse cardiovascular events in high-risk patients.

Register

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the relationship between achieved LDL-C, major cardiovascular outcomes, and safety at very low LDL-C levels.
  • Interpret the evidence from cardiovascular outcome trials with PCSK9 inhibitors and ezetimibe.
  • Describe the clinical application of non-statin, LDL-C-lowering therapies to reduce ASCVD risk.

Faculty

  • Susan Halli-Demeter, DNP, FNP-BC, CLS, FPCNA, FNLA
  • Ty Gluckman, MD, FACC